Vivos Therapeutics

VVOS · NASDAQ

$0.1406+$0.0057 (+4.23%)TodayMarket closed ·
Prev close $0.1349

Latest news

  • NewsAvi Kapoor

    Why 3M Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket

  • Press releaseGlobe Newswire

    Vivos Therapeutics Closes Acquisition of Stake in SOD Sciences and 50% Interest in Pseudohypoxia Test, Opening a Potential Path to Access More Than 325,000 New Patients Through the AHA Channel

  • Press releaseGlobe Newswire

    Vivos Therapeutics Agrees to Acquire Minority Stake in SOD Sciences and 50% Interest in Proprietary Pseudohypoxia Test

  • Press releaseGlobe Newswire

    Vivos Therapeutics Reports Progress in Material Cost Reductions and Revenue Growth Initiatives

  • News

    12 Health Care Stocks Moving In Wednesday's Pre-Market Session

  • News

    12 Health Care Stocks Moving In Tuesday's Intraday Session

  • NewsAvi Kapoor

    Why Pyxis Tankers Shares Are Trading Higher By Over 11%; Here Are 20 Stocks Moving Premarket

  • NewsAvi Kapoor

    Dow Falls Over 300 Points; SAIC Shares Jump After Upbeat Q2 Results

  • Press releaseGlobe Newswire

    Vivos Therapeutics and South Palm Cardiovascular Associates Sign Definitive Agreements to Launch Regional Sleep Testing and Treatment Center

  • News

    12 Health Care Stocks Moving In Tuesday's After-Market Session

  • Press releaseGlobe Newswire

    Vivos Therapeutics Reports Record New Patient Referrals at its Nevada Sleep & Airway Medicine Centers

  • News

    12 Health Care Stocks Moving In Friday's After-Market Session

  • Press releaseGlobe Newswire

    Vivos Therapeutics Opens New Sleep Testing and Treatment Facility in Nevada to Meet Rapidly Growing Patient Demand for Sleep Apnea Testing and Treatment

  • News

    Vivos Therapeutics Reports Q2 2026 Results: Full Earnings Call Transcript

  • Press releaseGlobe Newswire

    Vivos Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Update

  • Press releaseGlobe Newswire

    Vivos Therapeutics Schedules Release of Second Quarter 2026 Financial Results and Conference Call

  • News

    12 Health Care Stocks Moving In Wednesday's Intraday Session

  • News

    12 Health Care Stocks Moving In Wednesday's Pre-Market Session

  • News

    12 Health Care Stocks Moving In Tuesday's After-Market Session

  • Press releaseGlobe Newswire

    Vivos’ Vida® Appliance Shows Statistically Significant Improvement in Insomnia Severity in 100% of Study Participants

  • News

    12 Health Care Stocks Moving In Thursday's Pre-Market Session

  • News

    12 Health Care Stocks Moving In Friday's Pre-Market Session

  • News

    12 Health Care Stocks Moving In Friday's After-Market Session

  • Press releaseGlobe Newswire

    New Clinical Trial Data Published Showing Positive Results from Use of Vivos Technology to Treat Obstructive Sleep Apnea in Children

  • News

    Vivos Therapeutics Gains AMA Approval for New Medical Codes, Expanding Access to Sleep Apnea Treatment

  • Press releaseGlobe Newswire

    Vivos Therapeutics Granted CPT® Coverage and Reimbursement Codes for All Vivos CARE Oral Medical Devices From American Medical Association

  • NewsAvi Kapoor

    Crude Oil Gains Over 1%; Mobileye Global Shares Jump

  • NewsAvi Kapoor

    Dow Jumps Over 500 Points; FactSet Research Posts Upbeat Earnings

  • NewsHenry Khederian

    Why Vivos Therapeutics (VVOS) Stock Is Down 25% Today

  • NewsAvi Kapoor

    Nasdaq Surges 400 Points; US Jobless Claims Fall To 219,000

  • News

    Nvidia, T-Mobile US, Vivos Therapeutics, SoFi Technologies, Tesla: Why These 5 Stocks Are On Investors' Radars Today

  • NewsVandana Singh

    Vivos Therapeutics Says It Is Poised To Disrupt Pediatric Sleep Apnea Market, Secures FDA Approval For DNA Appliance To Treat Snoring In Children

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.